Key result
Reduced-dose DOACs cut major bleeding ~38% vs. full-dose regimens in VTE with similar efficacy.
Why the study?
Extended anticoagulation therapy is often required in patients with VTE, but the optimal dosing strategy remains unclear.
Does reduced-dose direct oral anticoagulants reduce bleeding and prevent recurrent VTE compared to full-dose in patients with venous thromboembolism requiring extended anticoagulation?
Meta-Analysis (n=8,781)
Yes
Does reduced-dose direct oral anticoagulants reduce bleeding and prevent recurrent VTE compared to full-dose in patients with venous thromboembolism requiring extended anticoagulation?
Reduced-dose direct oral anticoagulants offer a safer bleeding profile without compromising efficacy in preventing recurrent VTE and mortality during extended therapy.
Answers are grounded in this paper and cite their sources.
Supports reduced-dose DOACs for extended VTE therapy to lower bleeding risk; reinforces de-escalation evidence with preserved efficacy.
Background: Extended anticoagulation therapy is often required in patients with venous thromboembolism (VTE), but the optimal dosing strategy remains unclear. This study aimed to evaluate the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in the extended treatment of VTE. Methods: We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCT) comparing reduced-dose versus full-dose direct oral anticoagulants for extended anticoagulation therapy in VTE. Primary outcomes included major bleeding, recurrent VTE, all-cause mortality, and clinically relevant nonmajor bleeding. Secondary outcomes included pulmonary embolism and upper limb deep vein thrombosis. Statistical analysis was performed using R 4.4.2. Quality assessment of included RCT was conducted using the Cochrane Risk of Bias 2 tool. All included studies were assessed as having an overall low risk of bias. Conclusions: Reduced-dose anticoagulation demonstrates significantly lower bleeding risk compared to full-dose in VTE patients, with comparable efficacy in preventing recurrent VTE and mortality.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2026) conducted a meta-analysis in Venous thromboembolism (VTE) (n=8,781). Reduced-dose direct oral anticoagulants vs. Full-dose direct oral anticoagulants (e.g., apixaban 5 mg, rivaroxaban 20 mg) was evaluated on Major bleeding (RR 0.62, 95% CI 0.42-0.92, p=0.019). Reduced-dose direct oral anticoagulants reduced the risk of major bleeding by 38% compared to full-dose regimens in patients with venous thromboembolism, with comparable efficacy in preventing recurrent VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: